$CDLX

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million

Original reporting
Published Aug 5, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CDLX
Neutral
medium confidence
Mentioned
$CDLX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDLXNeutralMed
01

Why it matters

Traders can update near-term expectations using the disclosed Q3 guidance bands and assess whether the margin improvement narrative offsets continued YoY declines in revenue, billings, users, and cash flow.

02

Market read

Fresh quarterly metrics plus explicit Q3 guidance create a tradable setup into and during the earnings webcast.

03

What to watch

MQUs fell 17% YoY and ACPU declined, so the key question is whether Q3 guidance implies stabilization in unit economics or continued top-line shrinkage.

Relevance 7/10Novelty 8/10Timing: after-hours/earnings call today, Aug 5, 2026 at 5:00 PM ET

Background

This is an SEC Form 8-K with Exhibit 99.1 covering Cardlytics’ Q2 2026 financial results and Q3 2026 guidance ranges.

Company-level read

Ticker impact

$CDLXNeutralMedium confidence
Context

Cardlytics reported Q2 2026 results and provided Q3 2026 guidance ranges for Billings, Revenue, Adjusted Contribution, and Adjusted EBITDA.

Expected impact

Likely modest volatility around the earnings call and any market reaction to the guidance ranges versus expectations, with downside risk if investors focus on worsening net loss and cash burn.

Evidence & confidence

The filing discloses fresh quarterly datapoints (revenue, billings, net loss, FCF) plus explicit Q3 guidance ranges, which can drive repricing even without a beat/raise narrative.

Market effects

Signals ongoing pressure on purchase-intelligence monetization (declining billings, users) while emphasizing margin improvement and self-sustainability efforts.

No specific regional read-through beyond US and UK platform operations mentioned.

Limited global impact; primarily a US-listed ad-tech/purchase-intelligence name with UK exposure.

Counterpoint

Investors may discount the “within guidance” framing and focus on worsening net loss, operating cash outflow, and free cash flow deterioration versus the prior year.

Key entities

  • Cardlytics, Inc.

    Purchase intelligence platform reporting Q2 2026 results and issuing Q3 2026 guidance ranges.

  • Amit Gupta

    CEO quoted on execution translating into results and being within guidance across key metrics.

  • David Evans

    CFO quoted on sequential growth and self-sustainability plan.

Related articles

$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$LULUMed

JPMorgan resets Lululemon stock price target by 38%

JPMorgan cut Lululemon's (LULU) price target by 38% to $95, citing weak Q2 results and lower guidance. Revenue fell 4% to $2.4B, with North America and China sales declining. LULU stock is down 80% from highs. Boss maintained a 'Neutral' rating, noting challenges and high marketing costs.

$SUPVMed

Supervielle (SUPV) Swings Back To Profit As Layoffs Reshape The Bank

Grupo Supervielle (SUPV) reported a net income of AR$12.8 billion for Q2, reversing a prior loss, driven by a 17% workforce reduction and cost-cutting. Adjusted net income was AR$36.2 billion, with an adjusted ROAE of 12.4%. Lending metrics improved, with net interest income up 13.1% and NPL ratio at 5.5%. However, the bank posted a net loss of AR$5.4 billion for H1, with ROAA at 0.6% for Q2 and -0.1% for H1.

$DELLHighAI 9/10

Dell Stock Jumped 15% Last Week. Here's Why This Top AI Stock Is Still a Buy

Dell's stock rose 15% after reporting a 58% revenue increase to $47B, driven by AI infrastructure demand. AI-optimized server sales doubled to $16.4B, and traditional server revenue surged 122% to $10.5B. Adjusted earnings per share rose 203% to $7.04. Dell raised its full-year guidance, expecting 69% revenue growth to $192B and 148% earnings growth to $25.50 per share.

$GRNTMed

Granite Ridge (GRNT) Grows Profits While Costs Quietly Creep Higher

Granite Ridge Resources (GRNT) reported Q2 net income of $30M ($0.23/share), up from $25.1M a year ago, with production rising 1% to 32,044 Boe/d. The company added 21.9 net undeveloped locations via acquisitions and declared a $0.11/share dividend. Adjusted EBITDAX increased to $79.6M, but lease operating expenses rose 47% per barrel to $10.27. Oil prices rose, while natural gas prices fell.